menu search

AFMD / Down -26.45% in 4 Weeks, Here's Why Affimed N.V. (AFMD) Looks Ripe for a Turnaround

Down -26.45% in 4 Weeks, Here's Why Affimed N.V. (AFMD) Looks Ripe for a Turnaround
Affimed N.V. (AFMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. Read More
Posted: Oct 25 2023, 11:22
Author Name: Zacks Investment Research
Views: 111043

AFMD News  

Affimed to Participate in Upcoming Investor Conferences

By GlobeNewsWire
November 1, 2023

Affimed to Participate in Upcoming Investor Conferences

MANNHEIM, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncolog more_horizontal

Down -26.45% in 4 Weeks, Here's Why Affimed N.V. (AFMD) Looks Ripe for a Turnaround

By Zacks Investment Research
October 25, 2023

Down -26.45% in 4 Weeks, Here's Why Affimed N.V. (AFMD) Looks Ripe for a Turnaround

Affimed N.V. (AFMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. more_horizontal

Affimed to Present at the Cantor Global Healthcare Conference 2023

By GlobeNewsWire
September 21, 2023

Affimed to Present at the Cantor Global Healthcare Conference 2023

MANNHEIM, Germany, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncol more_horizontal

Affimed to Present at the H.C. Wainwright Annual Global Investment Conference

By GlobeNewsWire
September 7, 2023

Affimed to Present at the H.C. Wainwright Annual Global Investment Conference

HEIDELBERG, Germany, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving pati more_horizontal

Surprise! These 3 Penny Stocks Have Wall Street's Seal of Approval.

By InvestorPlace
August 23, 2023

Surprise! These 3 Penny Stocks Have Wall Street's Seal of Approval.

Although relative few investors – let alone analysts hired by top research institutions – give much thought to low-volume speculative securities, more_horizontal

Affimed N.V. (AFMD) Reports Q2 Loss, Misses Revenue Estimates

By Zacks Investment Research
August 10, 2023

Affimed N.V. (AFMD) Reports Q2 Loss, Misses Revenue Estimates

Affimed N.V. (AFMD) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate. more_horizontal

3 Cheap Stocks to Buy Under $1 in August 2023

By InvestorPlace
August 4, 2023

3 Cheap Stocks to Buy Under $1 in August 2023

The world of penny stocks is rife with potential pitfalls to avoid. Many firms trading at those prices are manipulated by actors with bad intent. more_horizontal

Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023

By GlobeNewsWire
August 3, 2023

Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023

HEIDELBERG, Germany, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patie more_horizontal


Search within

Pages Search Results: